期刊文献+

腹膜透析和血液透析对终末期肾病患者免疫功能的对比研究 被引量:23

下载PDF
导出
摘要 目的:探讨腹膜透析和血液透析对终末期肾病患者NK细胞和T细胞亚群的影响。方法:选取2010年6月~2014年3月我院收治的126例终末期肾病患者作为研究对象,按照治疗方法将患者随机分为腹膜透析组和血液透析组。腹膜透析组患者行非卧床持续性腹膜透析,血液透析组行常规血液透析。分别于透析前和透析后6个月采集静脉血,采用流式细胞术对两组患者血液中CD+3CD4、CD+3CD+8T淋巴细胞比例、CD4/CD8比值、调节性T细胞比例以及NK细胞的比例比较分析。采用MTT法检测NK细胞的活性。结果:腹膜透析组和血液透析组患者治疗前CD+3CD4、CD+3CD+8、CD4/CD8比值、调节性T细胞比例以及NK细胞的比例及活性比较差异无统计学意义(P〉0.05)。两组治疗后CD+3CD4T淋巴细胞比例、CD4/CD8比值、Treg细胞比例、NK细胞比例及活性较治疗前显著下降,而CD+3CD+8T淋巴细胞比例无变化(P〈0.05)。血液透析组患者治疗后外周血中CD+3CD4T淋巴细胞比例、CD4/CD8比值、Treg细胞比例、NK细胞比例及活性下降较腹膜透析组更为显著(P〈0.05)。两组治疗后组内CD+3CD+8T淋巴细胞水平比较差异无统计学意义(P〈0.05)。结论:腹膜透析和血液透析会导致患者免疫系统功能低下,其中血液透析对患者免疫系统影响更大。
出处 《中国中西医结合肾病杂志》 2015年第3期249-251,共3页 Chinese Journal of Integrated Traditional and Western Nephrology
  • 相关文献

参考文献15

  • 1Kaw D, Malhotra D. Platelet dysfunction and end - stage renal disease. Semin Dial,2006,19 (4) :317 - 322.
  • 2Israni AK, Xiong H,Liu J,et al. Predicting end - stage renal dis- ease after liver transplant. Am J Transplant,2013,13 (7) :1782 - 1792.
  • 3Bahirwani R, Forde KA, Mu Y, et al. End - stage renal disease after liver transplantation in patients with pre - transplant chronic kidney disease. Clin Transplant ,2014,28 ( 2 ) :205 - 210.
  • 4Palamidas AF, Gennimata SA, Karakontaki F,et al. Impact of he- modialysis on dyspnea and lung function in end stage kidney dis- ease patients. Biomed Res Int,2014,2014:212751.
  • 5Mayya M, Manjunath R, Gupta A. Peritoneal dialysis. J Indian Med Assoc,2013,111 (8) :529 - 533.
  • 6Filiopoulos V, Hadjiyannakos D, Takouli L, et al. Inflammation and oxidative stress in end -stage renal disease patients treated with hemodialysis or peritoneal dialysis, lnt J Artif Organs,2009, 32(12) :872-882.
  • 7叶任高.内科学第5版[M].北京:人民出版社,2000.837.
  • 8Gimdt M, Sester M,Sester U, et al. Defective expression of B7 - 2 (CD86) on monocytes of dialysis patients correlates to the ure- mia - associated immune defect. Kidney Int, 2001,59 ( 4 ) : 1382 - 1389.
  • 9Eleftheriadis T, Kartsios C, Yiannaki E, et al. Chronic inflamma- tion and T cell zeta- chain downregulation in hemodialysis pa- tients. Am J Nephro1,2008,28( 1 ) :152 - 157.
  • 10Eleftheriadis T, Kartsios C, Yiannaki E, et al. Decreased CD3+ CD16+ natural killer - like T - cell percentage and zeta - chain expression accompany chronic inflammation in haemodi- alysis patients. Nephrology ( Carlton ), 2009, 14 ( 5 ) : 471 - 475.

二级参考文献10

  • 1毕增祺.慢性肾功能衰竭[M].北京:中国协和医科大学出版社,2003,176-178.
  • 2Koc Y,Unsal A,Ahbap E, et al. Clinical outcome of diabetic peri- toneal dialysis patients and evaluation of factors affccting mortality: a single centre' s experience from Turkey [ J]. J Ren Care,2011, 37(2) :94-100.
  • 3Sarnak M, Jaber B. Mortality caused by sepsis in patients with end- stage renal disease compared with the normal population [ J ]. Kidney Int,2000,54 (4) :1758-1764.
  • 4Griveas I, Visvardis G, Fleva A, et al. Lymphocytes subsets in the course of continuous ambulatory peritoneal dialysis (CAPD) [ J ]. Ren Fail, 2004,26(6) : 641-646.
  • 5Griveas I, Visvardis G, Fleva A, et al. Comparative analysis of immunophenotypic abnormalities in cellular immunity of uremic patients undergoing either hemodialysis or continuous ambulatory peritoneal dialysis [ J ]. Ren Fail,2005,27 : 279-282.
  • 6Chansritrakul S, Eiam-Ong S, Kansanabuch T, et al. Continuous ambulatory peritoneal dialysis improves both the number and memo- ry function of CD4 T cells in uremic patients [ J ]. J Med Assoc Thai ,2004,87 (4) :389-394.
  • 7Caligiuri M A. Human natural killer cells [ J]. Blood, 2008,112 (8) :461-469.
  • 8Stenvinkel P, Wanner C, Metzger T, et al. Inflammation and outcome in end-stage renal failure :does female gender constitute a survival advantage.'? [ J ]. Kidney Int,2002,62 (5) : 1791-1798.
  • 9Kaysen G A. The microinflammatory state in uremia: causes and potential consequences [ J ] . J Am Soc Nephrol, 2001,12 ( 7 ) : 1549-1557.
  • 10伍凌云,张训,侯凡凡.尿毒症毒素在维持性血透患者细胞免疫缺陷中的作用[J].中华肾脏病杂志,1995,11(S1):3-5. 被引量:5

共引文献129

同被引文献241

引证文献23

二级引证文献158

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部